Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
January 07, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
FourKites Named to Inc.’s 2021 Best in Business List in the Logistics & Transportation Category
December 08, 2021 07:30 ET
|
FourKites
CHICAGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- FourKites®, the world’s leading real-time supply chain visibility platform, has been named to the Inc. 2021 Best in Business list in the Logistics and...
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
December 02, 2021 08:00 ET
|
Delcath Systems, Inc.
On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall...
Global Bile Duct Cancer Market to Surpass US$ 429.6 Million by 2028, expected to grow at a CAGR 12.8% over 2021-2028, Says Coherent Market Insights (CMI)
November 30, 2021 08:40 ET
|
CMI
SEATTLE, Nov. 30, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit...
Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
November 30, 2021 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems Announces Third Quarter 2021 Results
November 09, 2021 07:30 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021
November 08, 2021 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
November 05, 2021 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results
October 25, 2021 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
For the 2nd Consecutive Year, Liquipel Appears on the Inc. 5000, With Revenue Growth of 207 percent!
September 23, 2021 09:00 ET
|
Liquipel Assurance LLC
IRVINE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Inc. magazine today revealed that Liquipel is on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private...